International Stem Cell

International Stem Cell ROA

The Return on Assets (ROA) of International Stem Cell (ISCO) as of Nov 4, 2026 is -8.67 %. In the previous year, Return on Assets (ROA) was -4.04 % — a change of 114.69% (lower).

ROA

-8.67 %

YoY

114.69%

Last updated:

In 2025, International Stem Cell's return on assets (ROA) was -8.67 %, a 114.69% increase from the -4.04 % ROA in the previous year.

The International Stem Cell ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2018
-27.33 USD
Jan 1, 2019
-64.43 USD
Jan 1, 2020
-51.52 USD
Jan 1, 2021
-18.18 USD
Jan 1, 2022
-6.45 USD
Jan 1, 2023
-2.43 USD
Jan 1, 2024
-4.04 USD
Jan 1, 2025
-8.67 USD
The International Stem Cell ROA history
YEARROAYoY
-8.67 %+114.69%
-4.04 %+66.23%
-2.43 %-62.30%
-6.45 %-64.54%
-18.18 %-64.72%
-51.52 %-20.03%
-64.43 %+135.69%
-27.33 %-69.08%
-88.42 %+477.30%
-15.32 %-58.51%
-36.92 %-78.76%
-173.81 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

International Stem Cell Stock analysis

What does International Stem Cell do? International Stem Cell Corp (ISCO) is a biotechnology company founded in 2005 and headquartered in Carlsbad, California. It specializes in the development and manufacture of stem cell products for therapeutics and research purposes. ISCO specializes in the production of "human parthenogenetic stem cells" (hpSCs). This means that they produce stem cells from human egg cells that can replicate without fertilization by sperm. The company is a leader in this field and has filed over 80 patents worldwide. ISCO has various business areas, including life science research, therapeutics, dermatology, and animal health. The company partners with various industries, including academic institutions, pharmaceutical and biotechnology companies, and government agencies. One of their biggest partnerships is with the Chinese company Sino Biopharmaceuticals. ISCO offers a variety of products, including in vitro diagnostics for testing genetic diseases such as Huntington's and food allergies. However, the diagnostics division of the company is a small department primarily focused on research and development purposes. ISCO also has a dermatology division called Lifeline Skin Care, which manufactures skincare products based on human stem cells. These products have been developed for improving skin texture and reducing scars. Lifeline Skin Care is a luxury brand for skincare products currently sold in over 15 countries worldwide. In terms of animal health, ISCO recently launched a new division called Lifeline Animal Health. They are developing animal therapeutics based on hpSCs. The company has already developed the first animal therapeutic for dogs approved for the treatment of hip dysplasia. However, ISCO primarily focuses on the development of therapeutics for human stem cells. The company aims to be a global leader in the development of stem cell therapeutics. Their first product, CytoCor for heart disease, is already in clinical phase 1b/2a. The drug is intended to help reduce damage after a heart attack and improve heart function. ISCO also plans to develop therapeutics for other indications, including Alzheimer's disease, based on hpSCs. The company has a strong partnership with the California Institute for Regenerative Medicine, which focuses on stem cell research and their use in medicine. ISCO is a leading company in stem cell research and development. They have a unique approach to stem cell production and offer a variety of products and services for various industries. The company aims to develop groundbreaking stem cell therapeutics and change the way diseases are treated. International Stem Cell is one of the most popular companies on Eulerpool.

ROA Details

Understanding International Stem Cell's Return on Assets (ROA)

International Stem Cell's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing International Stem Cell's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider International Stem Cell's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in International Stem Cell’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about International Stem Cell stock

Return on Assets (ROA) of International Stem Cell is -8.67 % in 2025.

Return on Assets (ROA) of International Stem Cell changed from -4.04 % to -8.67 %, representing a 114.69% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) International Stem Cell since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s International Stem Cell with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — International Stem Cell

All Key Metrics — International Stem Cell